September marked a significant milestone in immunology, commemorating 50 years since the publication of a pivotal paper on interleukin-2 (IL-2), a protein crucial for T cell growth and regulation. As I reflect on this anniversary and its implications for science, I ponder a recurring question: What has IL-2 truly contributed to the field?
Defining IL-2's importance becomes complex. From my standpoint, it paved the way for the discovery of critical human retroviruses, including the one responsible for leukemia and ultimately HIV. This foundation facilitated evidence confirming HIV as the cause of AIDS and was instrumental in developing blood tests that helped safeguard our blood supply.
However, many of my peers might emphasize IL-2's role in enabling human T cell cultures, which opened avenues for cellular immunology and cancer immunotherapy. The interpretations vary, yet the overarching takeaway reminds us of the unpredictable nature of scientific advancements.
Reflecting on the initial motivations behind our research, we sought to identify growth factors necessary for culturing human blood cells for study. Discovering that we could cultivate T cells was a revelation. At that time, the prevailing belief was that continuous growth of these cells in culture was impossible. Ironically, shortly after our findings were published, a leading expert asserted that T cells could not be cultured, underscoring the skepticism that often surrounds transformative research.
Our work led directly to the identification of human T-cell leukemia virus-1 (HTLV-1), the first human retrovirus established to cause leukemia. This was a significant turning point, demonstrating how one discovery leads to another, enabling breakthroughs that were previously unimaginable. Who could have predicted that a more lethal infectious disease, AIDS, would follow, leveraging techniques we had developed for T cell analysis?
The ability to grow T cells fundamentally changed the trajectory of cellular immunology. Visionaries like Steve Rosenberg quickly recognized the potential of IL-2 to exploit the immune system against cancer, thus ushering in the era of cancer immunotherapy. His pioneering efforts, along with those of others in the field, laid the groundwork for invaluable cancer treatments.
The contributions stemming from our initial research are extensive. Rafi Ahmed’s work expanded our understanding of T cell memory, enhancing knowledge about the immune response to infections and vaccinations. Additionally, IL-2 set the stage for a myriad of interleukins and cytokines that orchestrate immune responses. The methodologies we employed became templates for exploring other cytokines, fostering a wider scientific inquiry than we had originally envisioned.
Our exploration didn’t aim for immediate therapeutic outcomes; it stemmed from a desire to unravel basic biological questions. This leads me to caution against the current trend of funneling research funding predominantly into projects promised with immediate results. Scientific progress thrives in the uncharted territories of inquiry, often yielding transformative findings from seemingly inconsequential questions.
Science's path isn't linear. Breakthroughs often emerge unexpectedly, and if funding is restricted to projects that guarantee short-term applicability, we may miss out on the vital discoveries that shape future medical landscapes. During my childhood, witnessing my sister's battle with leukemia left an indelible mark. Physicians undertook invasive procedures not for immediate cures, but for the benefit of future patients—a lesson that lingers in my mind today.
IL-2 serves as a testament to the unpredictable yet profound impact of basic science. While we understood its significance, we could only imagine a fraction of the subsequent scientific advancements that would arise from our curiosity.
As I look to the future, I remain hopeful that today’s scientists are unearthing questions that may not yet seem valuable but could very well revolutionize medicine in the generations to come.
Robert C. Gallo, M.D., is the founding director of the University of South Florida’s Institute for Translational Virology & Innovation, director of the microbial oncology program at the Tampa General Hospital Cancer Institute, and co-founder and international scientific director of the Global Virus Network. He is best known for his pioneering discovery of human retroviruses, including HIV as the cause of AIDS.